Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?
- 20 January 2021
- journal article
- letter
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 53 (3), 383-384
- https://doi.org/10.1016/j.dld.2020.12.123
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general populationDigestive and Liver Disease, 2020
- New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative StressNutrients, 2020
- Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective StudyClinical Gastroenterology and Hepatology, 2020
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsJournal of Hepatology, 2019
- Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis StageClinical Gastroenterology and Hepatology, 2019
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030Journal of Hepatology, 2018
- PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stressScientific Reports, 2017
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United StatesJournal of Hepatology, 2012
- Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidencesInternal and Emergency Medicine, 2012